• About
    • Our Team
    • Careers
    • Stories
  • Technology Transfer
    • Available Technologies
    • Innovators
      • Meet Our Innovators
      • Submit Disclosure
      • NAI Chapter
    • Startups
      • Meet Our Startups
    • Lab to Life
      • About Lab to Life
      • Lab to Life Process
      • Lab to Life Startups
      • Lab to Life Team
      • Lab to Life Contact
    • AI POC Grant Program
    • Workshops and Events
      • CSU Demo Day
    • FAQ
  • Real Estate Services
    • The Prospect
    • Maintenance Request Form
    • Commercial Leasing
  • Financing Program
  • Maxwell Ranch
  • Connect
  • Newsletter Signup
  • Submit Disclosure
  • About
    • Our Team
    • Careers
    • Stories
  • Technology Transfer
    • Available Technologies
    • Innovators
      • Meet Our Innovators
      • Submit Disclosure
      • NAI Chapter
    • Startups
      • Meet Our Startups
    • Lab to Life
      • About Lab to Life
      • Lab to Life Process
      • Lab to Life Startups
      • Lab to Life Team
      • Lab to Life Contact
    • AI POC Grant Program
    • Workshops and Events
      • CSU Demo Day
    • FAQ
  • Real Estate Services
    • The Prospect
    • Maintenance Request Form
    • Commercial Leasing
  • Financing Program
  • Maxwell Ranch
  • Connect
  • Newsletter Signup
  • Submit Disclosure

Biomolecule fractions and derivatives from Mycobacterium tuberculosis, leprae and other species

At a Glance

Due to its expertise in Mycobacterium research, Colorado State University has well established materials and methods for conducting research with various species of Mycobacterium, including M. tuberculosis, M. leprae and other species. These reagents include sterile culture filtrate extracts, inactivated cells, subcellular fractions, genomic DNA, lipid fractions, purified glycolipids, lipoglycans, lipids, and proteins.

Background

Traditionally, studying the various fractions of Mycobacterium has been difficult as few labs have the capabilities to prepare and study the various fractions of Mycobacterium. As a deadly disease that still kills 1.25 million people annually, being able to identify the specific molecules within the bacteria responsible for the immune response, toxicity, or allergenic properties associated with TB is still important in developing new methods of treatment for Mycobacterium.

Overview

Available Materials – Item Description and Unit Size
Low Yield Irradiated Cells (X001)
  • M. tb, Irradiated Cells, Strain H37Rv, Hypoxic Culture, 1 g
  • M. tb, Irradiated Cells, Strain H37Rv, Normoxic Culture, 1 g
  • M. leprae, Irradiated Cells, Strain NHDP, Dry 10 mg
  • M. bovis, Irradiated Cells 1 g
  • M. bovis, Irradiated Cells (95-1315) 1 g
  • M. bovis, Irradiated Cells (TB17-02518) 0.5 g
  • M. leprae, Irradiated Cell, Strain Br4923, Dry 10 mg
  • M. leprae, Irradiated Cell, Strain Thai-53, Dry 10 mg

 

Subcellular Fractions (X002)

Whole Cell Lysate/Sonicate (WCL/WCS)

  • M. tb, Whole Cell Lysate (WCL), Strain H37Rv 10 mg
  • M. tb, Whole Cell Lysate (WCL), Strain CDC1551 (also referred to as CSU93 or Oshkosh) 10 mg
  • M. tb, Whole Cell Lysate (WCL), Strain HN878 10 mg
  • M. tb, Whole Cell Lysate (WCL), Strain Indo-Oceanic (T17X) 10 mg
  • M. tb, Whole Cell Lysate (WCL), Strain East African Indian (91_0079) 10 mg
  • M. bovis, Whole Cell Lysate (WCL) 2 mg
  • M.leprae, Whole Cell Sonicate (WCS) 2 mg
  • M.avium, Whole Cell Lysate (WCL), Strain (K10)(BAA968) 5 mg

Culture Filtrate Proteins (CFP)

  • M. tb, Culture Filtrate Proteins (CFP), Strain H37Rv 1 m
  • M. tb, Culture Filtrate Proteins (CFP), Strain CDC1551 (also referred to as CSU93 or Oshkosh) 1 mg
  • M. tb, Culture Filtrate Proteins (CFP), Strain HN878 1mg
  • M. bovis, Culture Filtrate Proteins (CFP) 1 mg
  • M. tb, Mycobacterial extracellular vesicle (MEV) enriched CFP 0.05 mg
  • M. tb, Mycobacterial extracellular vesicle (MEV) depleted CFP 0.25 mg

Cell Wall (CW)

  • M. tb, Cell Wall (CW), Strain H37Rv 1 mg
  • M. tb, Cell Wall (CW), Strain CDC1551 (also referred to as CSU93 or Oshkosh) 1 mg
  • M. tb, Cell Wall (CW), Strain HN878 1 mg
  • M. bovis, Cell Wall (CW) 1 mg

Cell Membrane (MEM)

  • M. tb, Cell Membrane (MEM), Strain H37Rv 1 mg
  • M. tb, Cell Membrane (MEM), Strain CDC1551 (also referred to as CSU93 or Oshkosh) 1 mg
  • M. tb, Cell Membrane (MEM), Strain HN878 1 mg
  • M. bovis, Cell Membrane (MEM) 1 mg
  • M. canetti, Cell Membrane (MEM) 1 mg

Cytosol (CYT)

  • M. tb, Cytosol (CYT), Strain H37Rv 1 mg
  • M. tb, Cytosol (CYT), Strain CDC1551 (also referred to as CSU93 or Oshkosh) 1 mg
  • M. tb, Cytosol (CYT), Strain HN878 1 mg
  • M. tb, Cytosol (CYT), Strain Indo-Oceanic (T17X) 1 mg
  • M. bovis, Cytosol (CYT) 1 mg
  • M. canetti, Cytosol (CYT) 1 mg

Extracted Protein Pools

  • M. tb, Soluble Cell Wall Proteins (SCWP) 1 mg
  • M. tb, TX-114 Extractable Proteins 1 mg
Genomic DNA (X003)
  • M. leprae, Genomic DNA, Strain NHDP-63 2 ug
  • M. leprae, Genomic DNA, Strain Thai-53 2 ug
  • M. leprae, Genomic DNA, Strain Br4923 2 ug
  • M.bovis, genomic DNA (95-1315) 80 ug
  • M.bovis, genomic DNA (TB17-02518) 25 ug
  • M. tuberculosis, genomic DNA (any strain) 50 ug
    recPlasmid – containing Mycobacterium spp gene product; E. coli expression 1 ug
Crude Lipids (X004)

Cell wall core, mAGP (Mycolylarabinogalatan Peptidoglycan complex)

  • M. tb, mAGP (Mycolylarabinogalatan Peptidoglycan complex), Strain H37Rv 5 mg
    Total Lipid (TLIP)

Total Lipid (TLIP)

  • M. tb, Total Lipid (TLIP), Strain H37Rv 5 mg
  • M. tb, Total Lipid (TLIP), Strain CDC1551 (also referred to as CSU93 or Oshkosh) 5 mg
  • M. tb, Total Lipid (TLIP), Strain HN878 5 mg
  • M. leprae, Total Lipid (TLIP) 0.5 mg
  • M. tb, Total Lipid (TLIP), Strain H37Rv, Hypoxic Culture 1 mg
  • M. tb, Total Lipid (TLIP), Strain H37Rv, Normoxic Culture 1 mg
  • M. bovis, Total Lipid (TLIP) 5 mg
Purified Lipids (X005)
  • M. tb, Acetone Soluble Lipids 0.5 mg
  • M. tb, Acetone Insoluble Lipids 0.5 mg
  • M. tb, Trehalose Dimycolate (TDM) 0.25 mg
  • M. tb, Sulfolipid-1 (SL-1) 0.25 mg
  • M. tb, Phosphotidylinositol mannosides (PIM) 1/2 0.5 mg
  • M. tb, Arabinogalactan (AG) 1 mg
  • M. tb, Peptidoglycan (PG) 0.5 mg
  • M. tb, Mycolic Acids (MAME) 1 mg
  • M. tb, Phthiocerol dimycocerosate (PDIM) 0.5 mg
  • M. leprae, Phenolic glycolipid (PGL-1) 1 mg
  • ND-O-BSA (synthetic PGL-I glycoconjugate) – OLD VIAL TYPE 0.25 mg
  • ND-O-HSA (synthetic PGL-I glycoconjugate) – OLD VIAL TYPE 0.25 mg
  • M. canetti, Phenolic glycolipid (PGL-1) 0.25 mg
  • M. tb Mycobactin 0.1 mg
  • M.tb, Trehalose Monomycolate (TMM) 0.25 mg
  • 6-O-methylglucose-containing lipopolysaccharides (mGLP) 0.1 mg
Lipoglycans (X006)
  • M. tb H37Rv, Lipoarabinomannan, (LAM) 0.5 mg
  • M. tb H37Rv, Lipomannan (LM) 0.1 mg
  • M. tb H37Rv, Phosphotidylinositol mannosides 6 (PIM6) 0.25 mg
  • M. smegmatis, Liporabinomannan (smegLAM) 0.5 mg
  • M. leprae, Lipoarabinomannan (lepLAM) 0.1 mg
  • M. tb H37Rv, Demannosylated Lipoarabinomannan (dLAM) 0.25 mg
High Yield Native Proteins (X007)
  • Ag85 Complex (mixture of Rv3804c, Rv1886c, Rv0129c) 0.5 mg
  • 45kDa Glycoprotein (Mpt32, Apa, Rv1860) 0.5 mg
  • 16kDa Protein (HspX, alpha-crystallin, Rv2031c) 0.1 mg
  • GroES Protein (Rv3418c) 0.5 mg
  • 16kDa Protein (HspX, alpha-crystallin, Rv2031c) 0.1 mg
Low Yield Native Proteins (X010)
  • Ag85A (Rv3804c) 0.25 mg
  • Ag85B (Rv1886c) 0.25 mg
  • Ag85C (Rv0129c) 0.25 mg
  • 38kDa Protein (PhoS1, Rv0934) 0.25 mg
High Yield Irradiated Cells (Small Scale) (X011)
  • M. tb, Irradiated Cells, Strain H37Rv 1 g
  • M. tb, Irradiated Cells, Strain CDC1551 (also referred to as CSU93 or Oshkosh) 1 g
  • M. tb, Irradiated Cells, Strain HN878 1 g
Small Quantity Low Yield Native Proteins (X008)
  • Ag85A (Rv3804c) 0.1 mg
  • Ag85B (Rv1886c) 0.1 mg
  • Ag85C (Rv0129c) 0.1 mg
  • 38kDa Protein (PhoS1, Rv0934) 0.1 mg
  • Mpt64 Protein (Rv1980c) 0.1 mg
  • Rv1411 Protein 0.1 mg
Recombinant Proteins (X012)
  • Various; purified from E. coli (1 mg/vial minimum; quantity varies based on production yield). Over 3000 various proteins available. Inquire about specific proteins and availability. 1 mg

Benefits

  • Reagents developed in a BSL3 laboratory – made safe for others to use
  • Cost savings in not having to hire specialty labs
  • High quality and purity
  • Quality control protocols in place for each reagent
  • Free SOPs to use materials

Applications

  • Allergenicity and toxicity
  • Vaccine development
  • Antigen characterization
  • Immune response
  • Proteomic Analysis
Last Updated: January 2026
Opportunity

Materials are available through CSU Strata via non-exclusive licensing (list of available materials below). Please email steve.foster@colostate.edu for information about licensing the materials.

Inventors

Karen Dobos
John Belisle
Megan Lucas

Reference Number
2026-034
Licensing Manager

Steve Foster
steve.foster@colostate.edu
970-491-7100

Download PDF
Download
Strata logo white
  • Technology Transfer
  • Real Estate Services
  • Financing Program
  • Maxwell Ranch
  • Connect
  • Equal Opportunity Employer
  • Tax Information
  • Technology Transfer
  • Real Estate Services
  • Financing Program
  • Maxwell Ranch
  • Connect
  • Equal Opportunity Employer
  • Tax Information
Serving the Colorado State University System with strategic real estate services, intellectual property protection and licensing, and financing activities.
Integrity
Reliability
Respect
Innovation
Excellence
Submit Disclosure

Newsletter Sign Up

Connect